Table 4.
Treatment-related adverse events of grade ≥3a
Grade | AE related to | ILIXA/SUN (N = 58) | SUN (N = 30) | Total (N = 88) |
---|---|---|---|---|
n (%) | n (%) | n (%) | ||
3 | SUN | 13 (22.4) | 5 (16.7) | 18 (20.5) |
ILIXA | 2 (3.4) | NA | 2 (2.3) | |
4 | SUN | 1 (1.7) | 2 (6.7) | 3 (3.4) |
ILIXA | 0 (0.0) | NA | 0 (0.0) | |
5 | SUN | 0 (0.0) | 1 (3.3) | 1 (1.1) |
ILIXA | 0 (0.0) | NA | 0 (0.0) |
AE = adverse event; ILIXA = ilixadencel; NA = not available; SUN = sunitinib.
Common Terminology Criteria for Adverse Events version 5.0.